Celldex is collaborating with Bristol-Myers Squibb for the development of varlilumab and Bristol-Myers’ nivolumab in a phase I/II study. This deal marks the growing interest in the field of immuno-oncology.
The BlackBerry Z3 will be available to customers from July 8, 2014 through carrier 3 Hong Kong, and authorized partners including Broadway, Fortress, Wilson, Suning, Chung Yuen, Nuance Watson and CMK.
Gallant Leon, Managing Director for Hong Kong and Taiwan at BlackBerry said, "Hong Kong is a key market for us and we are excited to be working with our partners to bring in the BlackBerry Z3 to customers here. This device gives users more ways to connect, share and communicate, providing the best tool for secure, reliable communications and collaboration with friends, family and co-workers. Priced affordably, the BlackBerry Z3 will extend the full capabilities of the BlackBerry 10 Operating System version 10.2.1 experience for a new generation of customers in Hong Kong."
Are you in Hong Kong and tempted? For the money the Z3 sure is good value. It may not be quite as high spec as the Z30, but it sure is a beautiful BlackBerry and I speak from experience - I have one.
SAMSUNG is Garbage, AMAZON deal is starting point but next is Google, the next deal with BBRY .
•With striking similarities between Alexion and Celldex's products, the latter's next move could determine long-term investment value. Of course CDX1135 only being tested on a rare condition called dense deposit disease (DDD);
I concluded that with success, CDX-1135 could become the next Soliris over the next decade as there are many other indications Alexion Pharma is looking to expand Soliris' label into other indications as well including the prevention of DGF in renal transplant patients where Solaris being under clinical trials.
CDX-1135 was the fourth maybe fifth most talked about product in Celldex's pipeline last year. It was being tested to treat a disease that affects just 300-500 patients in the U.S., and for this indication has very limited fundamental upside. Yet, it's similar to Alexion Pharmaceuticals's (ALXN) Soliris, which is what made it so attractive.
Soliris is a complement modulator, and works by binding to a component called C5, which has been linked to several genetic and blood diseases. Alexion Pharmaceuticals has grown to a $35 billion company with just this one single FDA approved drug, which earned $1.55 billion in sales last year. Currently, Soliris is approved to treat a life-threatening genetic disorder atypical hemolytic uremic syndrome and the blood disease paroxysmal nocturnal hemoglobinuria, but is being studied to treat five additional conditions. If successful at treating all diseases, some analysts predict peak sales reaching $5 billion worldwide due to Alexion's ability to price the drug sky-high in treating these ultra-rare conditions.
Now, back to Celldex: CDX-1135 works in the same way, binding to the exact same component. The only difference is that it also binds to the C3 component, which is why many long-term investors, including myself, believe that CDX-1135 is a secret value buried deep within the company's pipeline. Because after all, given the success of Soliris, conventional wisdom implies that CDX-1135 could be tested to treat various rare diseases, could be priced high, and would support an Alexion-like premium multiple once CDX-1135 is proven successful in clinical trials.
Merck is hoping this acquisition provides it with a serious hepatitis C contender to Gilead Sciences' blockbuster drug, Sovaldi. At the end of Q1 2014, Merck had approximately $15.8 billion in cash and cash equivalents on its balance sheet. After factoring
I said Solaris sales $2 Billion and about CLDX-1135 ClinicalTrials.gov processed this record on June 23, 2014 But haven't got the update from Celldex yet.
Solaris $1.5Billion Sales in 2013 - Mkt Cap for ALXN $32Billion = CLDX atleast expected to be $20Billion Mkt Cap Management guidance is that final results on ReACT will be available in 2H, 2014. ... comparable to Alexion's (ALXN) $1.5 billion blockbuster drug Solaris. .... Read more on Alternative Investing
CDX- 1135. It is a soluble complement inhibitor that targets both C3 and C5. This drug was developed by Avant (acquired by Celldex) which called this drug TP10. It is a technology that is similar to that which Alexion has led to extraordinary success for ultra-rare orphan diseases with its lead drug Solaris; had sales on $2 billion in 2013 and Alexion currently has a market capitalization of $32 billion.
Last stock offering underwriters paid $24, Bristol's up-front payment was small relative to upfront payments made by big pharma and big biotechs in the past year, but the real benefit to Celldex is in the renegotiation of its license with Medarex and the potential to cozy up more closely with Bristol's promising oncology business.
The bottom line is this, the lead investigator for DCVax-Direct, Dr. Subbiah from M.D. Anderson, indicated early on that this DCVax-Direct trial would have a decade long impact on cancer treatment and the early evidence from this trial supports his assertion. The German PEI validation of the DCVax platform and Dr. Subbiah's remarks placed in the context of these early results provide more than enough evidence that a great deal of investment derisking has already taken place. Those who do not understand or accept this may be fooled into buying NWBO stock low and selling lower which is what momentum traders are prone to do when A.F. attacks come as a surprise. Others are waiting as you are for further validation. This will mean a buy in at a much higher price but with much more certain prospects. This represents a change in your investment strategy from when you were invested in IMUC before it fell so hard but in this context, readers will be able to understand that most of your statements are made in defense of this new investment position. There is absolutely nothing wrong with this as long as it is not being superimposed, as superior, upon other strategies that are just as valid.
Meaning of PR from MD Anderson is that - IN OPEN LABLE UNBLINDED STUDY - MD ANDRSON will disclose results only at the end of the study. But if company wants to disclose they can at their discretion and results are documented in patients file.
So were is REBUKE? What MD Anderson said is - It is Open Lable Unblinded Study where MD Anderson is not obliged to publish the results where as company can publish finding at their discretions.
Adam is well paid basher of bigger pharma and his agenda is slowly coming to light. Otherwise Why he should take so much interest. ADAM is deputed by Bigger Pharma to stop NWBO GETTING BIGGER LIKE AMGEN